pharma · Obesity · Type 2 diabetes
NovoThirteen is a pharma organization headquartered in Bagsværd, JP. Primary therapeutic focus areas include Obesity, Type 2 diabetes, Type 2 Diabetes, Mild cognitive impairment (MCI) or mild dementia, both of the Alzhei
Approved · small molecule · Obesity
Wegovy is a pre-filled pen formulation of semaglutide (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg FlexTouch solution for injection) approved for obesity treatment. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces appetite and promotes weight loss through central nervous system signaling. Sp
Internal code NN9536-7752
Wegovy is a pre-filled pen formulation of semaglutide (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg FlexTouch solution for injection) approved for obesity treatment. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that reduces appetite and promotes weight loss through central nervous system signaling. Sponsor NovoThirteen (Novo Nordisk) markets this product across multiple regulatory jurisdictions including the United States, European Union, Japan, Australia, and China. The program is currently in active approved status with regulatory clearance achieved in major markets. The latest disclosed milestone involves a long-term weight maintenance study in adolescents with obesity receiving semaglutide 2.4 mg subcutaneously once-weekly. Wegovy represents a significant expansion of semaglutide's therapeutic reach beyond its original diabetes indication (OZEMPIC), establishing a dedicated obesity treatment franchise. The product is available in multiple dose strengths to support titration protocols and individualized dosing strategies.
Obesity affects a substantial global population and represents a significant unmet medical need, with limited pharmacological options historically available. Wegovy addresses this gap by offering a GLP-1 receptor agonist specifically formulated and indicated for chronic weight management in adults and adolescents with obesity. The drug's mechanism—reducing appetite and promoting satiety through GLP-1 pathway activation—provides a distinct pharmacological approach compared to older weight-loss agents. Market relevance is substantial: obesity is associated with multiple comorbidities including type 2 diabetes, cardiovascular disease, and metabolic syndrome, creating a large addressable patient population. Competitive positioning is strengthened by Wegovy's approval across multiple geographies and dose strengths, enabling flexible treatment protocols. The adolescent indication represents a significant clinical expansion, addressing obesity in younger populations where treatment options remain limited. Commercial significance is substantial given the chronic nature of obesity treatment, potential for long-term patient engagement, and integration with diabetes management in patients with comorbid conditions. Regulatory approvals in Australia (with PBS listing), European Union, Japan, and United States establish Wegovy as a globally accessible obesity treatment, differentiating it from competitors with more limited geographic availability.
Drug Class: GLP-1 receptor agonist
Modality: Small molecule (peptide)
Route of Administration: Subcutaneous injection via pre-filled pen (FlexTouch)
Active Ingredient: Semaglutide
Formulations: Available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses
Therapeutic Class: Alimentary tract and metabolism (ATC A10)
Related Therapies: OZEMPIC (semaglutide for type 2 diabetes), SAXENDA (liraglutide for obesity)
First Approval: Regulatory approvals achieved in United States, European Union, Japan, and Australia; specific approval dates for Wegovy obesity indication not yet disclosed in provided facts
Patent Status: Not yet disclosed
Also known as: obesity, obesity disease
A disorder involving an excessive amount of body fat.
ClinicalTrials.gov lists 50 registered studies for Obesity (Disorder) (AACT aggregate).
Phase breakdown: NA (46), PHASE4 (3), PHASE3 (1)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0011122), Orphanet — obesity disorder, NCT03412149, NCT06787001, NCT06852391, NCT06881485, NCT06911918, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Obesity indication approved
Wegovy approved in multiple jurisdictions for chronic weight management in adults and adolescents with obesity.
Adolescent weight maintenance study
Long-term treatment with semaglutide 2.4 mg subcutaneously once-weekly for weight maintenance in adolescents with obesity.
The obesity pharmacotherapy market includes multiple approved agents with varying mechanisms and regulatory status. SAXENDA (liraglutide, Teva Pharma GmbH) is an approved GLP-1 receptor agonist competitor for obesity, sharing the same mechanism class as Wegovy but with different pharmacokinetics and dosing frequency. Older agents in the competitive set include ONGLYZA (saxagliptin, AstraZeneca), ACTOS (pioglitazone, Alphapharm), TRAJENTA (linagliptin, Boehringer Ingelheim), and NESINA (alogliptin, Lacuna Pharma)—primarily DPP-4 inhibitors and thiazolidinediones originally developed for type 2 diabetes with secondary metabolic effects. FORXIGA (dapagliflozin, AstraZeneca) and INVOKANA (canagliflozin, Teva) represent SGLT-2 inhibitor class competitors with modest weight-loss properties. ZYNQUISTA (canagliflozin, Lexicon Pharmaceuticals) is a newer SGLT-2 inhibitor. Repaglinide-based agents (REPAGLINIDE SUN, Teva) represent meglitinide class alternatives. Wegovy's competitive advantage derives from its GLP-1 mechanism, which produces superior weight loss compared to most competing agents, combined with its availability in multiple dose strengths supporting individualized titration and its approval specifically for obesity rather than as a secondary indication. The competitive landscape reflects a shift toward GLP-1 agonists as preferred pharmacotherapy for obesity management.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| ONGLYZA | AstraZeneca | — | approved |
| ACTOS | Alphapharm Pty Ltd | — | approved |
| REPAGLINIDE SUN | Teva Pharma GmbH | — | approved |
| VIPIDIA | Takeda | — | approved |
| TRAJENTA | Boehringer Ingelheim Pty Ltd | — | approved |
| NESINA | Lacuna Pharma Pty Ltd | — | approved |
| ZYNQUISTA | LEXICON PHARMACEUTICALS, INC. | — | approved |
| SAXENDA | Teva Pharma GmbH | — | approved |
| FORXIGA | AstraZeneca | — | approved |
| QTRILMET | Takeda | — | approved |
| TRAZEC | Teva Pharma GmbH | — | approved |
| INVOKANA | Teva Pharma GmbH | — | approved |
| SIBUTRAMINE | — | Monoamine transporter inhibitor | Approved |
| SETMELANOTIDE ACETATE | — | Melanocortin receptor 4 agonist | Approved |
| SETMELANOTIDE | — | Melanocortin receptor 4 agonist | Approved |
| RIMONABANT | — | Cannabinoid CB1 receptor antagonist | Approved |
| PHENTERMINE HYDROCHLORIDE | — | Norepinephrine transporter releasing agent | Approved |
| PHENTERMINE | — | Norepinephrine transporter releasing agent | Approved |
| PHENDIMETRAZINE TARTRATE | — | Norepinephrine transporter inhibitor | Approved |
| ORLISTAT | — | Pancreatic lipase inhibitor | Approved |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
United States (FDA): Semaglutide approved; application numbers NDA209637, NDA213051, NDA213182, NDA215256, NDA218316 on record. Wegovy obesity indication approved status confirmed.
European Union (EMA): Approved; Marketing Authorization Holder is Novo Nordisk A/S. EMA product numbers include EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/005422, EMEA/H/C/006426. Authorisation dates recorded as 26/03/2026, 30/03/2026.
Japan (PMDA): Approved; semaglutide approval recorded March 2023.
Australia (TGA): Approved with PBS listing. PBS codes include 12075M, 12080T, 14149Q, 14163K, 14844G, 14846J, 15311W, 15322K. Sponsor: Novo Nordisk Pharmaceuticals Pty. Limited. First listed dates: 2020-07-01, 2024-06-01, 2025-06-01.
China (NMPA): Clinical trial status; NCT05877547 indicates ongoing clinical development in China.
Wegovy is approved for chronic weight management in adults and adolescents with obesity. It is indicated as a treatment for obesity, a chronic metabolic disorder affecting a large global population.
Wegovy contains semaglutide, a GLP-1 receptor agonist that activates glucagon-like peptide-1 receptors in the central nervous system, reducing appetite and promoting satiety, thereby supporting weight loss and weight maintenance.
Wegovy is manufactured and marketed by NovoThirteen (Novo Nordisk). In Australia, the sponsor is Novo Nordisk Pharmaceuticals Pty. Limited; in the European Union, the Marketing Authorization Holder is Novo Nordisk A/S.
Wegovy is available in five dose strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, all formulated as FlexTouch pre-filled pen solutions for subcutaneous injection.
Wegovy is administered as a subcutaneous injection once-weekly using a pre-filled FlexTouch pen. The specific injection technique and site rotation recommendations are provided in product labeling.
Yes, Wegovy is approved by the FDA. Multiple NDA applications (NDA209637, NDA213051, NDA213182, NDA215256, NDA218316) are on record, and the product is marketed for obesity indication in the US.
Yes, Wegovy is approved by the European Medicines Agency (EMA). Novo Nordisk A/S holds the Marketing Authorization, with EMA product numbers EMEA/H/C/004174, EMEA/H/C/004953, EMEA/H/C/005422, and EMEA/H/C/006426.
Yes, semaglutide (the active ingredient in Wegovy) was approved in Japan by the PMDA in March 2023 for obesity treatment.
Yes, Wegovy is approved in Australia and is listed on the Pharmaceutical Benefits Scheme (PBS) with multiple PBS codes (12075M, 12080T, 14149Q, 14163K, 14844G, 14846J, 15311W, 15322K), making it subsidized for eligible patients.
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone regulating appetite and blood glucose. It reduces hunger signals and promotes satiety through central nervous system pathways, supporting weight loss.
Specific pivotal trial details are not fully disclosed in available facts. However, an ongoing trial (NCT 2023-508055-40-00) evaluates long-term weight maintenance in adolescents with obesity receiving semaglutide 2.4 mg once-weekly; results are not yet reported.
Yes, Wegovy is approved for adolescents with obesity. An ongoing clinical trial (NCT 2023-508055-40-00) is evaluating long-term weight maintenance in this population with semaglutide 2.4 mg once-weekly.
Both Wegovy and OZEMPIC contain semaglutide as the active ingredient. OZEMPIC is approved for type 2 diabetes treatment, while Wegovy is specifically indicated for obesity. They represent different therapeutic applications of the same drug.
Key competitors include SAXENDA (liraglutide, also a GLP-1 agonist for obesity), and older agents such as FORXIGA (dapagliflozin, SGLT-2 inhibitor), INVOKANA (canagliflozin, SGLT-2 inhibitor), and various DPP-4 inhibitors (ONGLYZA, TRAJENTA, NESINA) originally developed for diabetes with secondary metabolic effects.
Wegovy is not yet approved in China. Clinical trial NCT05877547 is ongoing in China, indicating that regulatory approval in that market is still under development.
Wegovy is classified in the Alimentary tract and metabolism category (ATC A10), reflecting its role in metabolic regulation and weight management.
Patent status information for Wegovy is not yet disclosed in available regulatory and clinical data sources.
NN9536-7752 → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Wegovy represents Novo Nordisk's deliberate market segmentation strategy, establishing a dedicated obesity franchise separate from its diabetes portfolio (OZEMPIC). The multi-dose formulation strategy (0.25–2.4 mg) enables flexible titration protocols and accommodates diverse patient populations, reducing treatment discontinuation due to tolerability issues. Approval across geographies (US, EU, Japan, Australia) with ongoing China trials signals global commercialization ambitions in a high-growth obesity market.
Competitive Implications: Wegovy's GLP-1 mechanism and superior weight-loss efficacy position it favorably against older-generation competitors (DPP-4 inhibitors, thiazolidinediones, SGLT-2 inhibitors) and directly compete with SAXENDA. The adolescent indication expansion creates differentiation, as few obesity pharmacotherapies have robust pediatric data. Geographic regulatory approval breadth exceeds most competitors, particularly in premium markets (Australia PBS listing, EU, Japan).
Future Catalysts: Completion and reporting of the adolescent weight maintenance trial (NCT 2023-508055-40-00) will provide long-term efficacy and safety data in younger populations, potentially supporting label expansion and market penetration in pediatric obesity. China clinical trial progression (NCT05877547) represents significant commercial opportunity given obesity prevalence in Asia-Pacific. Additional label expansions (e.g., cardiovascular outcome trials, comorbidity-specific indications) remain possible.
Expected Milestones: Adolescent trial data readout timing not yet disclosed. China regulatory approval timeline not yet disclosed. Peak sales projections and consensus positioning not yet disclosed.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.